You have 9 free searches left this month | to do more

abt-263

Abt 263 is a drug used to treat Solid Tumors, Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma, and other conditions. Abt 263 is being actively studied in 2 studies and prior, has been studied in 14.

Top SponsorsTop SitesTop Investigators
AbbVieCHU
AbbVie (prior sponsor, Abbott)CHU Besancon - Hopital Jean Minjoz
AbbottCentre Antoine LACASSAGNE
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Active, not recruiting
  • CD20-Positive Lymphoid Malignancies
  • +3 more
  • Tucson, Arizona
  • +5 more
2022-03-22
Mar 22, 2022
A
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • ABT-263
  • La Jolla, California
  • +9 more
2021-07-28
Jul 28, 2021
A
Completed
  • Chronic Lymphoid Leukemia
  • +5 more
  • ABT-263
  • Los Angeles, California
  • +11 more
2021-07-28
Jul 28, 2021
C
Completed
  • Platinum-resistant or Refractory Ovarian Cancer
  • ABT-263
  • Besançon, France
  • +15 more
2019-03-15
Mar 15, 2019
A
Completed
  • Small Cell Lung Cancer
  • Small Cell Lung Carcinoma
  • ABT-263
  • Peoria, Arizona
  • +17 more
2018-06-01
Jun 1, 2018
A
Completed
  • Lymphoid Malignancy
  • Solid Tumors
  • ABT-263
  • (no location specified)
2017-11-17
Nov 17, 2017
A
Completed
  • Solid Tumors
  • ABT-263
  • +3 more
  • Santa Monica, California
  • +3 more
2017-11-16
Nov 16, 2017
A
Completed
  • Solid Tumors
  • (no location specified)
2017-11-17
Nov 17, 2017
A
A
Completed
  • Lymphoma
  • +2 more
  • San Antonio, Texas
    Site Reference ID/Investigator# 25068
2010-12-16
Dec 16, 2010
A
Completed
  • Healthy Female Subjects
  • ABT-263
  • Waukegan, Illinois
    Site Reference ID/Investigator# 23602
2010-11-08
Nov 8, 2010
A
Completed
  • Chronic Lymphocytic Leukemia
  • +2 more
  • ABT-263
  • Encinitas, California
  • +4 more
2010-10-06
Oct 6, 2010